---
title: "Lvpai Group reports Q3 net loss of USD 7,100"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274878827.md"
datetime: "2026-02-04T22:23:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274878827.md)
  - [en](https://longbridge.com/en/news/274878827.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274878827.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274878827.md) | [繁體中文](https://longbridge.com/zh-HK/news/274878827.md)


# Lvpai Group reports Q3 net loss of USD 7,100

Lvpai Group Ltd. reported its financial results for the third quarter ended October 31, 2025. For the three-month period, the company recorded a net loss of USD 7,100. For the nine-month period ended October 31, 2025, net loss was USD 24,565. The company reported no revenue or gross profit for the three and nine months ended October 31, 2025. As of October 31, 2025, Lvpai Group Ltd. reported cash and cash equivalents of USD 0 and negative operating cash flows of USD 19,465. The company indicated that its working capital requirements remain significant, and it continues to rely on previous financing activities for liquidity and capital resources. Management also noted that recently issued accounting pronouncements are not expected to have a material impact on its financial condition or results of operations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lvpai Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-000624), on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [Enstar Group Limited (ESGR.US)](https://longbridge.com/en/quote/ESGR.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Aptorum Group Limited (APM.US)](https://longbridge.com/en/quote/APM.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/en/news/279032442.md)
- [Will KETAFREE Become The First FDA-Approved Preservative-Free Ketamine Formulation?](https://longbridge.com/en/news/279285510.md)
- [Capricor Theraputics Q4 revenue falls to zero, net loss widens](https://longbridge.com/en/news/278939139.md)
- [Clene 2025 net loss narrows as expenses fall](https://longbridge.com/en/news/278880252.md)
- [Century Therapeutics 2025 net loss narrows beating estimates](https://longbridge.com/en/news/278880556.md)